Utility of pulmonary function test screening for bronchiolitis obliterans syndrome stage 0-p among recipients of allogeneic hematopoietic stem cell transplantation conditioned with antithymocyte globulin

References

• Kwok WC, Liang BM, Lui MMS, et al. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. Respirology. 2019;24(5):459–466. doi:10.1111/resp.13472.
   PubMed Web of Science ®Google Scholar
• Diab M, ZazaDitYafawi J, Soubani AO. Major pulmonary complications after hematopoietic stem cell transplant. Exp Clin Transplant. 2016;14(3):259–270. doi:10.6002/ect.2015.0275.
   PubMed Web of Science ®Google Scholar
• Gazourian L, Rogers AJ, Ibanga R, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014;89(4):404–409. doi:10.1002/ajh.23656.
   PubMed Web of Science ®Google Scholar
• Pham J, Rangaswamy J, Avery S, et al. Updated prevalence, predictors and treatment outcomes for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. Respir Med. 2020;177:106286. doi:10.1016/j.rmed.2020.106286.
   PubMed Web of Science ®Google Scholar
• Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266–274. doi:10.1016/j.bbmt.2014.10.021.
   PubMed Web of Science ®Google Scholar
• Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome ­epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1072–1078. doi:10.1016/j.bbmt.2010.11.018.
   PubMed Web of Science ®Google Scholar
• Vieira AG, Funke VA, Nunes EC, Frare R, Pasquini R. Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49(6):812–817. doi:10.1038/bmt.2014.25.
   PubMed Web of Science ®Google Scholar
• Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Jama. 2009;302(3):306–314. doi:10.1001/jama.2009.1018.
   PubMed Web of Science ®Google Scholar
• Glanville AR, Benden C, Bergeron A, et al. Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. ERJ Open Res. 2022;8(3):00185-2022. doi:10.1183/23120541.00185-2022.
   PubMedGoogle Scholar
• Duque-Afonso J, Ihorst G, Waterhouse M, et al. Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2018;24(11):2277–2284. doi:10.1016/j.bbmt.2018.06.024.
   PubMed Web of Science ®Google Scholar
• Jamani K, He Q, Liu Y, et al. Early post-transplantation spirometry is associated with the development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(5):943–948. doi:10.1016/j.bbmt.2019.12.002.
   PubMed Web of Science ®Google Scholar
• Kitko CL, Pidala J, Schoemans HM, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplant Cell Ther. 2021;27(7):545–557. doi:10.1016/j.jtct.2021.03.033.
   PubMedGoogle Scholar
• Hachem RR, Chakinala MM, Yusen RD, et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med. 2004;169(4):468–472. doi:10.1164/rccm.200307-1018OC.
   PubMed Web of Science ®Google Scholar
• Lama VN, Murray S, Mumford JA, et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med. 2005;172(3):379–383. doi:10.1164/rccm.200501-097OC.
   PubMed Web of Science ®Google Scholar
• Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21(3):297–310. doi:10.1016/s1053-2498(02)00398-4.
   PubMed Web of Science ®Google Scholar
• Abedin S, Yanik GA, Braun T, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant. 2015;21(6):1127–1131. doi:10.1016/j.bbmt.2015.02.006.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in ­patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–173. doi:10.1016/S1470-2045(15)00462-3.
   PubMed Web of Science ®Google Scholar
• Kröger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43–53. doi:10.1056/NEJMoa1506002.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte ­globulin to assess impact on chronic graft-versus-host disease-free ­survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35(36):4003–4011. doi:10.1200/JCO.2017.75.8177.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7(2):e100–e111. doi:10.1016/S2352-3026(19)30220-0.
   PubMed Web of Science ®Google Scholar
• Shiratori S, Sugita J, Ota S, et al. Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021;56(1):129–136. doi:10.1038/s41409-020-0985-3.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–864. doi:10.1016/S1470-2045(09)70225-6.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e381.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144.
   Web of Science ®Google Scholar
• Chen Y, Xu J, Fan Z, et al. Retrospective analysis of bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2021;138(Supplement 1):4877–4877. doi:10.1182/blood-2021-150602.
   Google Scholar
• Turner J, He Q, Baker K, et al. Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease. Transplant Cell Ther. 2021;27::616.e611–616.e616.
   Google Scholar
• Alkhunaizi M, Patel B, Bueno L, et al. Risk factors for bronchiolitis obliterans syndrome after initial detection of pulmonary impairment after hematopoietic cell transplantation. Transplant Cell Ther. 2023;29:204.e201–204.e207.
   Google Scholar
• Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168(2):208–214. doi:10.1164/rccm.200212-1468OC.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10):657–666. doi:10.1016/s1083-8791(03)00242-8.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Lim A, Panek-Hudson Y, et al. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(6):781–786. doi:10.1016/j.bbmt.2014.02.011.
   PubMed Web of Science ®Google Scholar